Percheron Therapeutics Gestion

Gestion contrôle des critères 1/4

Le PDG Percheron Therapeutics est James Garner, nommé en Aug2023, a un mandat de 1.25 ans. La rémunération annuelle totale est A$ 824.68K, composée du salaire de 52.7% et des bonus 47.3%, y compris les actions et options de la société. détient directement 0.13% des actions de la société, d'une valeur de A$ 101.75K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.3 ans et 3.1 ans.

Informations clés

James Garner

Directeur général

AU$824.7k

Rémunération totale

Pourcentage du salaire du PDG	52.7%
Durée du mandat du directeur général	1.3yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	1.3yrs
Durée moyenne du mandat des membres du conseil d'administration	3.1yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de James Garner a-t-elle évolué par rapport aux bénéfices de Percheron Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	AU$825k	AU$434k	-AU$12m
Mar 31 2024	n/a	n/a	-AU$11m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$11m
Jun 30 2023	AU$34k	n/a	-AU$11m

Rémunération vs marché: La rémunération totale de James ($USD 535.86K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 297.90K ).

Rémunération et revenus: La rémunération de James a augmenté alors que l'entreprise n'est pas rentable.

PDG

James Garner (51 yo)

1.3yrs

Titularisation

AU$824,684

Compensation

Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, serves as Non-Executive Director at Percheron Therapeutics Limited (formerly known as Antisense Therapeutics Limited) since May 08, 2023 and has been its...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
James Garner	CEO, MD & Director	1.3yrs	AU$824.68k	0.13% A$ 101.7k
Deborah Ambrosini	Company Secretary & CFO	less than a year	AU$324.32k	pas de données
Anthony Filippis	Chief Operating Officer	1.8yrs	AU$596.05k	pas de données
Cathryn Clary	Chief Medical Advisor	no data	pas de données	pas de données

1.3yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de PER n'est pas considérée comme expérimentée (ancienneté moyenne 1.3 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
James Garner	CEO, MD & Director	1.5yrs	AU$824.68k	0.13% A$ 101.7k
Ben Price	Independent Non-Executive Director	3.1yrs	AU$113.77k	0.094% A$ 74.0k
Charmaine Gittleson	Independent Non-Executive Chair	3.7yrs	AU$220.29k	0.069% A$ 54.3k

3.1yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de PER sont considérés comme expérimentés (ancienneté moyenne 3.1 ans).

Percheron Therapeutics Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

High number of new and inexperienced directors

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Less than half of directors are independent

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Recent updates

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

New minor risk - Shareholder dilution

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Forecast to breakeven in 2027

High number of new and inexperienced directors

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

New major risk - Financial position

New minor risk - Shareholder dilution

New minor risk - Share price stability

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.20

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi